Efficacy of Duloxetine for the Treatment of Generalized Anxiety Disorder: Implications for Primary Care Physicians
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: This study examined the efficacy and tolerability of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine, for the treatment of patients with generalized anxiety disorder (GAD). METHOD: Patients were ≥ 18 years old and recruited from 5 European countries, the United States, and South Africa. The study had a 9-week, multicenter, randomized, double-blind, fixed-dose, placebo-controlled, parallel-group design. A total of 513 patients (mean age = 43.8 years; 67.8% female) with a DSM-IV-defined GAD diagnosis received treatment with duloxetine 60 mg/day (N = 168), duloxetine 120 mg/day (N = 170), or placebo (N = 175). The primary efficacy measure was the Hamilton Rating Scale for Anxiety (HAM-A) total score. Secondary measures included the Sheehan Disability Scale, HAM-A psychic and somatic anxiety factor scores, and HAM-A response, remission, and sustained improvement rates. The study was conducted from July 2004 to September 2005. RESULTS: Both groups of duloxetine-treated patients demonstrated significantly greater improvements in anxiety symptom severity compared with placebo-treated patients as measured by HAM-A total score and HAM-A psychic and somatic anxiety factor scores (p values ranged from ≤ .01 to ≤ .001). Duloxetine-treated patients had greater functional improvements in Sheehan Disability Scale global and specific domain scores (p ≤ .001) than placebo-treated patients. Both duloxetine doses also resulted in significantly greater HAM-A response, remission, and sustained improvement rates compared with placebo (p values ranged from ≤ .01 to ≤ .001). The rate of study discontinuation due to adverse events was 11.3% for duloxetine 60 mg and 15.3% for duloxetine 120 mg versus 2.3% for placebo (p ≤ .001). CONCLUSION: The results of this study demonstrate that duloxetine 60 mg/day and 120 mg/day were efficacious and well tolerated and thus may provide primary care physicians with a useful pharmacologic intervention for GAD. CLINICAL TRIALS REGISTRATION: ClinicalTrials.gov identifier NCT00122824.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wang, P. S., Berglund, P., Olfson, M., Pincus, H. A., Wells, K. B., & Kessler, R. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.6.603 · Cited by 1,325
Hospital Anxiety and Depression Scale
Zigmond, A. S., & Snaith, R. P. (2013) · PsycTESTS Dataset · doi:10.1037/t03589-000 · Cited by 946
Wang, P. S., Berglund, P., & Kessler, R. C. (2000) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2000.9908044.x · Cited by 686 · cited 1×
“One of the primary challenges for patients with GAD is access to empirically validated, evidence-based treatment interventions.(34,35) Within the primary care setting, there is a paucity of studies examining treatment interventions and outcomes for the GAD population.”
BackgroundShear, M. K., Vander Bilt, J., Rucci, P., Endicott, J., Lydiard, B., Otto, M. W., Pollack, M. H., Chandler, L., Williams, J., Ali, A., et al. (2001) · Depression and Anxiety · doi:10.1002/da.1033 · Cited by 483
Detke, M. J., Lu, Y., Goldstein, D. J., Hayes, J. R., & Demitrack, M. A. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0407 · Cited by 384 · cited 1×
“Duloxetine is a dual reuptake inhibitor of both serotonin and norepinephrine that has demonstrated efficacy for the treatment of major depression and diabetic peripheral neuropathic pain.(13,14) Within studies of major depression, duloxetine was shown to significantly reduce anxiety symptoms as measured by the Hamilto…”
BackgroundSelf-citationBecker, E. S., Goodwin, R., Hölting, C., Hoyer, J., & Margraf, J. (2003) · Journal of Nervous & Mental Disease · doi:10.1097/01.nmd.0000092198.20420.fc · Cited by 31 · cited 1×
“Although patients with GAD often express that they worry about “everything,” their most predominant concerns are about family, personal health, and the health of others.(4) Thus, the mutual reinforcements among the process of worry, focus on health, and the experience of multiple somatic symptoms result in patients wi…”
BackgroundThe rater applied performance scale: development and reliability
Lipsitz, J., Kobak, K., Feiger, A., Sikich, D., Moroz, G., & Engelhard, A. (2004) · Psychiatry Research · doi:10.1016/j.psychres.2004.03.001 · Cited by 31 · cited 2×
“Diagnosis was determined by psychiatrists based on clinical interview supplemented by the MiniInternational Neuropsychiatric Interview for DSM-IV.18 Raters from each research center underwent training in the Structured Interview Guide for the Hamilton Rating Scale for Anxiety (SIGH-A)19 and were evaluated for their in…”
Method
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“Antidepressants (SSRIs & SNRIs): Evidence from RCTs supports the use of SSRIs including escitalopram [544-552] and sertraline [556,559-561], as well as the SNRIs duloxetine [566-571] and venlafaxine XR [548,553,570-580] (all Level 1) for the first-line treatment of GAD.”
BackgroundBandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Russell, J. I., Mease, P. J., Smith, T. R., Kajdasz, D. K., Wohlreich, M. M., Detke, M. J., Walker, D. J., Chappell, A. S., & Arnold, L. M. (2008) · Pain · doi:10.1016/j.pain.2008.02.024 · Cited by 367
Self-citationEfficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis
Baldwin, D., Woods, R., Lawson, R., & Taylor, D. (2011) · BMJ · doi:10.1136/bmj.d1199 · Cited by 285
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Fava, G. A., Benasi, G., Lucente, M., Offidani, E., Cosci, F., & Guidi, J. (2018) · Psychotherapy and Psychosomatics · doi:10.1159/000491524 · Cited by 209
Systematic review and meta-analysis: dose-response curve of SSRIs and SNRIs in anxiety disorders
Jakubovski, E., Johnson, J. A., Nasir, M., Müller-Vahl, K., & Bloch, M. H. (2019) · Depression and Anxiety · doi:10.1002/da.22854 · Cited by 131
Gomez, A. F., Barthel, A. L., & Hofmann, S. G. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1472767 · Cited by 125
Roest, A. M., de Jonge, P., Williams, C. D., de Vries, Y. A., Schoevers, R. A., & Turner, E. H. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.15 · Cited by 101
Hoertel, N., Le Strat, Y., Blanco, C., Lavaud, P., & Dubertret, C. (2012) · Depression and Anxiety · doi:10.1002/da.21937 · Cited by 61
Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine
Trivedi, M. H., Desaiah, D., Ossanna, M. J., Pritchett, Y. L., Brannan, S. K., & Detke, M. J. (2008) · International Clinical Psychopharmacology · doi:10.1097/yic.0b013e3282f41d7e · Cited by 59
“The efficacy and safety of SNRIs, including duloxetine, have been demonstrated extensively in clinical trials in the treatment of MDD, GAD, DPNP, and FMS. Owing to their relatively selective action on 5-HT and NE, the SNRIs have tolerability profiles similar to SSRIs, but may also provide better efficacy than compound…”
BackgroundInfluentialSelf-citationLong-Term Safety, Tolerability, and Efficacy of Duloxetine in the Treatment of Fibromyalgia
Mease, P. J., Russell, I. J., Kajdasz, D. K., Wiltse, C. G., Detke, M. J., Wohlreich, M. M., Walker, D. J., & Chappell, A. S. (2010) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2008.11.001 · Cited by 54
Self-citationChoy, E. H. S., Mease, P. J., Kajdasz, D. K., Wohlreich, M. M., Crits-Christoph, P., Walker, D. J., & Chappell, A. S. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1203-2 · Cited by 47
“disorder (GAD), diabetic peripheral neuropathic pain (DPNP), and FM [18–32].”
BackgroundIncidence and Nature of Antidepressant Discontinuation Symptoms
Kalfas, M., Tsapekos, D., Butler, M., McCutcheon, R. A., Pillinger, T., Strawbridge, R., Bhat, B. B., Haddad, P. M., Cowen, P. J., Howes, O. D., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.1362 · Cited by 42
Pollack, M. H., Endicott, J., Liebowitz, M., Russell, J., Detke, M., Spann, M., Ball, S., & Swindle, R. (2008) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2007.11.006 · Cited by 35
“In each of these trials, duloxetine treatment significantly improved anxiety symptom severity for patients with GAD (Hartford et al., 2007; Koponen et al., 2007; Rynn et al., 2007).”
BackgroundSelf-citationSafer, D. J. (2016) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000564 · Cited by 19
Antidepressants versus placebo for generalised anxiety disorder (GAD)
Kopcalic, K., Arcaro, J., Pinto, A., Ali, S., Barbui, C., Curatoli, C., Martin, J., & Guaiana, G. (2025) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012942.pub2 · Cited by 16
Metadata
- Authors
- Koponen, H., Allgulander, C., Erikson, J., Dunayevich, E., Pritchett, Y., Detke, M. J., Ball, S. G., & Russell, J. M.
- Venue
- The Primary Care Companion to The Journal of Clinical Psychiatry
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2007-04-16
- Volume
- 09
- Issue
- 02
- Pages
- 100-107
- ISSN
- 1523-5998 (ISSN-L)
- OpenAlex
- W2076728061
- Cited by
- 91
- References
- 7
- FWCI
- 15.02
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.